Inspira™ Technologies Prepares its First Life-Support Systems for Deployment at a Leading U.S. Hospital

Core Viewpoint - Inspira Technologies has successfully delivered its INSPIRA™ ART100 systems to Glo-Med Networks Inc. for deployment in a leading U.S. hospital, marking a significant step in introducing its innovative respiratory support technology to the market [1][2]. Company Overview - Inspira Technologies is focused on revolutionizing life support and respiratory treatment with its Augmented Respiration Technology (INSPIRA™ ART), which aims to potentially replace the $19 billion mechanical ventilation market [4]. - The company targets the 20 million intensive care unit patients with acute respiratory failure annually, offering a non-ventilator solution that stabilizes oxygen saturation levels quickly while allowing patients to remain awake during treatment [4]. Product Development and Regulatory Approvals - The INSPIRA™ ART100 system has received FDA 510(k) clearance for use in cardiopulmonary bypass (CBP) procedures and has also obtained Israeli AMAR certification for both Extra-Corporeal Membrane Oxygenation and CBP procedures [5]. - The INSPIRA™ ART100 is designed in collaboration with leading U.S. clinicians and is set to integrate with the HYLA™ continuous blood monitoring technology, which is currently undergoing clinical evaluations [3]. Market Strategy - The initial deployment of the INSPIRA™ ART100 systems will target hospitals on the U.S. east coast, specifically a top-ranked New York hospital's cardiothoracic surgery division, to facilitate collaboration and brand introduction [2]. - The company aims to leverage these deployments to familiarize physicians and perfusionists with its technologies and brand [2].